Trial Profile
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of Tofacitinib (Cp-690,550) In Chinese Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Conventional Synthetic Dmard
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 03 Jun 2023 Results of pooled data from (NCT01877668/NCT01882439/NCT03486457/NCT01976364) assessing ong-term safety/efficacy of tofacitinib in TNFi-inadequate responder (IR) and biologic disease-modifying antirheumatic drug (bDMARD)-naive PsA pts presented at the 24th Annual Congress of the European League Against Rheumatism
- 17 Jul 2021 Status changed from recruiting to completed.
- 13 Apr 2021 Planned number of patients changed from 195 to 204.